We could not find your search for GSK Please try again.
Please check our suggestions as you type in the search box.
You can't get away from the need for good yield in an era of commodity inflation.
Let's look at five holdings that stayed in his portfolio for at least a year.
These four names in particular have made some stunning moves.
Klarman's hedge funds' top small-cap picks generate significant alpha.
Adam Feuerstein, Sr. Columnist for TheStreet, says Dynavax Technologies is the next big thing to watch in biotech.
Now is the time to pop the pharmaceutical pill and buy.
Aug 28, 2012 | 8:03 AM EDT
GSK downgraded to Neutral from Buy, UBS said. $48.18 price target. Valuation, earnings visibility limit potential for further upside.
Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data
. Company fundamental data provided by Morningstar
. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.